Associate Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. David J. Inwards, MD
|
|
Give Review
David J. Inwards, MD practices Hematology. He researched medicine at University of Nebraska Medical Center. University of Nebraska Medical Center is a one of the best medicals schools. University of Nebraska Medical Center is ranked 60 in research and 4 in primary care medicine David J. Inwards, MD is a published doctor and has 69 publications published. The lastest was: 'Large B-cell transformation in nodular lymphocyte predominant Hodgkin lymphoma: forty-year experience from a single institution.' He accepts all Medicare patients.
Publications
- Large B-cell transformation in nodular lymphocyte predominant Hodgkin Lymphoma: forty-year experience from a single institution.
- A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin Lymphoma.
- Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin Lymphoma.
- Spontaneous complete remission of angioimmunoblastic T-cell Lymphoma.
- Early Failure of Frontline Rituximab-containing Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma does not Predict Futility of Autologous Hematopoietic Cell Transpla...
- Infused Autograft Lymphocyte to Monocyte Ratio and Survival in Diffuse Large B-Cell Lymphoma.
- Widespread use of complementary and alternative medicine among non-Hodgkin Lymphoma survivors.
- Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma.
- Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outc...
- Outcomes of hematopoietic cell transplantation for diffuse large B cell Lymphoma transformed from follicular Lymphoma.
- Autologous or Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chemotherapy-Sensitive Mantle-Cell Lymphoma: Analysis of Transplantation...
- Autologous haematopoietic cell transplantation for non-Hodgkin Lymphoma with secondary CNS involvement.
- Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation.
- Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma.
- Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Researc...
- A phase i trial of immunostimulatory CpG 7909 oligodeoxynucleotide and (90) yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-hodgkin Lymphoma.
- Patients with immunoglobulin light chain amyloidosis undergoing autologous stem Cell transplantation have superior outcomes compared with patients with multiple myelom...
- Impact of Pretransplantation Conditioning Regimens on Outcomes of Allogeneic Transplantation for Chemotherapy-Unresponsive Diffuse Large B Cell Lymphoma and Grade III ...
- Autologous and allogeneic transplantation for burkitt Lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transpl...
- Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell Lymphoma: a cohort analysis from the center for international blood and marrow ...
- Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem Cell mobilization.
- Paraneoplastic lower motor neuronopathy associated with Hodgkin Lymphoma.
- Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure.
- Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin Lymphoma using lower intensity conditioning: a report from the CIBMTR.
- The Absolute Monocyte Count is Associated with Overall Survival in Patients Newly Diagnosed with Follicular Lymphoma.
- Clinicopathologic and genetic characterization of follicular Lymphomas presenting in the ovary reveals 2 distinct subgroups.
- Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic Leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory Lymphomas.
- Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell Lymphoma.
- Patients with celiac disease and B-cell Lymphoma have a better prognosis than those with T-cell Lymphoma.
- Predicting survival for diffuse large B-cell Lymphoma patients using baseline neutrophil/lymphocyte ratio.
- Composite hodgkin and non-hodgkin Lymphoma of the mitral and aortic valves.
- Vitamin D insufficiency and prognosis in non-Hodgkin's Lymphoma.
- Diagnosis and management of Waldenström Macroglobulinemia: Mayo stratification of Macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
- A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem Cell conditioning regimen in patients with multiple myeloma.
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin Lymphoma.
- PAX5-positive T-cell anaplastic large cell Lymphomas associated with extra copies of the PAX5 gene locus.
- New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem Cell transplantation in patient...
- A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell Lymphoma: a report from the CIBMTR.
- Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin Lymphoma.
- Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in...
- Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell Lymphoma.
- Autologous stem Cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisc...
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
- Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central C...
- Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin Lymphoma: a prospective study.
- Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's Lymphoma.
- Allogeneic transplants in follicular Lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.
- Treatment of benign orbital pseudoLymphomas with the monoclonal anti-CD20 antibody rituximab.
- AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin Lymphoma.
- A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untr...
- Response to rituximab in patients with type II cryoglobulinemia.
- Absolute values of immunoglobulin free light chains are prognostic in patients with primary Systemic amyloidosis undergoing peripheral blood stem cell transplantation.
- Primary Lymphomas of bone.
- Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell Lymphoma.
- Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary Systemic amyloidosis.
- Oprelvekin-associated bilateral optic disk edema.
- Prognostication of survival using cardiac troponins and N-terminal pro-Brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral bl...
- Superior survival in primary Systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.
- Therapeutic options in patients with Lymphoma and severe liver dysfunction.
- Acute neuropathies after peripheral blood stem cell and bone marrow transplantation.
- Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular Lymphoma.
- Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.
- Stem cell transplantation for the management of primary Systemic amyloidosis.
- Infused autograft lymphocyte to monocyte ratio predicts survival in classical Hodgkin Lymphoma.
- The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell Lymphomas.
- Day 100 Peripheral Blood Absolute Lymphocyte/Monocyte Ratio and Survival in Classical Hodgkin's Lymphoma Postautologous Peripheral Blood Hematopoietic Stem Cell Transp...
- Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin Lymphoma.
Schools
Mayo Medical School
Massachusetts General Hospital
Mayo Clinic Rochester
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Nebraska Medical Center -
Mayo School of Graduate Medical Education -
Massachusetts General Hospital -
Mayo Medical School
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1164409827 | |
| NPPES Provider LastName | INWARDS | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 183.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164409827 |
| Last Name Of The Provider | INWARDS |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Gita Thanarajasingam, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mrinal M. Patnaik, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Saravut J. Weroha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles Erlichman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shernan G. Holtan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael E. Menefee, MD |
|
|
Dr. Scott H. Kaufmann, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. William G. Morice, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tow S. Tan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wilson I. Gonsalves, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carola A. Arndt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert C. Miller, MD |
|
|
Dr. Kaaren K. Reichard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Minetta Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rahma M. Warsame, MD
This Doctor is OpenDoctor Recommended.
|